CONCORD.BO · BSE
Concord Drugs Limited
₹75.83
-4.15% (-₹3.28)
Prev. close
₹79.11
Volume
7,672
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Concord Drugs Limited
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, injectables such as small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. Concord Drugs Limited was incorporated in 1995 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Seelam Nagi Reddy
Headquarters
Hyderabad
Employees
250
Website
concorddrugs.inExchange
View on BSE ↗Key stats
Market cap
₹104.23 Cr
P/E ratio (TTM)
47.1
EPS (TTM)
₹1.68
Beta (1Y · daily vs NIFTY 50)
0.44
Beta (5Y · monthly vs NIFTY 50)
1.06
Shares float
43.53 L
EPS · quarter ended Jun 2026
₹0.85
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.5% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹51.36 Cr | ₹58.96 Cr | ₹52.08 Cr | ₹44.92 Cr | ₹45.24 Cr | ₹78.74 Cr | |
| EBITDA | ₹3.31 Cr | ₹5.69 Cr | ₹4.60 Cr | ₹4.05 Cr | ₹4.11 Cr | ₹4.49 Cr |
| ₹3.28 Cr | ₹1.59 Cr | ₹98.55 L | ₹47.23 L | ₹33.62 L | ₹1.06 Cr | |
| Diluted EPS | ₹3.75 | ₹1.82 | ₹1.06 | ₹0.47 | ₹0.34 | ₹0.95 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹58.23 Cr | ₹58.81 Cr | ₹65.14 Cr | ₹74.89 Cr | |
| — | — | ₹16.96 Cr | ₹17.52 Cr | ₹19.24 Cr | ₹14.51 Cr | |
| Stockholders' equity | — | — | ₹31.70 Cr | ₹33.82 Cr | ₹34.11 Cr | ₹48.51 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1.66 Cr | ₹79.23 L | ₹3.72 Cr | ₹-6.77 Cr | |
| Investing cash flow | — | — | ₹-2.27 Cr | ₹-1.01 Cr | ₹-2.32 Cr | ₹-1.13 Cr |
| — | — | ₹62.40 L | ₹28.34 L | ₹-1.43 Cr | ₹8.06 Cr | |
| Capital expenditure | — | — | ₹-85.66 L | ₹-1.02 Cr | ₹-2.33 Cr | ₹-1.17 Cr |
| End cash position | — | — | ₹7.84 L | ₹14.54 L | ₹12.09 L | ₹27.81 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Concord Drugs Limited | ₹97.50 Cr | ₹74 | 44.0 | 2.01 | 2.2% | 0.30 | +74.0% | +10.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Concord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to know
Livemint · 3 days ago
Concord Drugs Consolidated June 2026 Net Sales at Rs 20.94 crore, up 53.89% Y-o-Y
Moneycontrol.com · 1 month ago